JB Chemicals rises after Panoli facility completes US FDA audit with no observations

The inspection was conducted from 3 March 2025 to 7 March 2025.

The said audit has been successfully completed by the US FDA with 'no observations' and thus no Form 483 was issued.

Following this announcement, the scrip advanced 1.43% to currently trade at Rs 1599.95 on the BSE.

The company remains committed to producing quality products, embedding a quality culture across the organization and continuously investing in systems, processes & training of its employees so that it can maintain the highest standards of quality and compliance for all its markets,' JB Chemicals stated.

JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radio-diagnostics, APIs, and intermediates.